survivin (D-8): sc-17779. Western blot analysis of survivin expression in untreated (A) and Oxaliplatin (sc-202270) treated (B) HCT 116 whole cell lysates. Note down regulation of survivin expression in lane B.
Oxaliplatin (CAS 61825-94-3)
See product citations (8)
Application:
Oxaliplatin is a potent anti-neoplastic agent that binds to DNA and shows efficacy in Cisplatin resistant cell lines
CAS Number:
61825-94-3
Purity:
≥98%
Molecular Weight:
397.3
Molecular Formula:
C8H14N2O4Pt
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the efficacy of its progenitor, Cisplatin (sc-200896), the first of this class of anti-neoplastic agents. Oxaliplatin displays higher cytotoxicity and lower nephrotoxicity than Cisplatin (sc-200896) or Carboplatin (sc-202093), and shows antitumor activity in cell lines with acquired Cisplatin (sc-200896) resistance. The enhanced activity of Oxaliplatin compared to other members of this class is attributed to the bulky diaminocyclohexane ligand in the major groove that might limit the flexibility of the Oxaliplatin-DNA adduct, and interfere with DNA repair enzymes differently.
Oxaliplatin (CAS 61825-94-3) References
- Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. | Culy, CR., et al. 2000. Drugs. 60: 895-924. PMID: 11085200
- Oxaliplatin: a review of evolving concepts. | Mani, S., et al. 2002. Cancer Invest. 20: 246-63. PMID: 11901545
- Oxaliplatin: new opportunities for the treatment of gastrointestinal cancer. | MacDonald, JS. 2002. Cancer Invest. 20: 287-9. PMID: 11901548
- Cellular and molecular pharmacology of oxaliplatin. | Raymond, E., et al. 2002. Mol Cancer Ther. 1: 227-35. PMID: 12467217
- Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research? | Hill, EJ., et al. 2012. Crit Rev Oncol Hematol. 83: 353-87. PMID: 22309673
- Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. | Vietor, NO. and George, BJ. 2012. J Oncol Pharm Pract. 18: 355-9. PMID: 22333669
- Oxaliplatin-related thrombocytopenia. | Jardim, DL., et al. 2012. Ann Oncol. 23: 1937-1942. PMID: 22534771
- Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review. | Niu, J. and Mims, MP. 2012. J Clin Oncol. 30: e312-4. PMID: 22987080
- XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis. | Ye, F., et al. 2013. Cancer Chemother Pharmacol. 71: 733-40. PMID: 23299794
- TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. | Zhou, S., et al. 2021. Cell Death Dis. 12: 463. PMID: 33966039
- SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer. | Huang, JQ., et al. 2021. J Transl Med. 19: 280. PMID: 34193174
- Memantine ameliorates oxaliplatin-induced neurotoxicity via mitochondrial protection. | Wang, Y., et al. 2022. Bioengineered. 13: 6688-6697. PMID: 35235756
- KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. | Shen, X., et al. 2022. Cell Death Dis. 13: 303. PMID: 35379798
- A Novel Protein Encoded by Exosomal CircATG4B Induces Oxaliplatin Resistance in Colorectal Cancer by Promoting Autophagy. | Pan, Z., et al. 2022. Adv Sci (Weinh). 9: e2204513. PMID: 36285810
- Oxaliplatin disrupts nucleolar function through biophysical disintegration. | Schmidt, HB., et al. 2022. Cell Rep. 41: 111629. PMID: 36351392
Inhibitor of:
AChRα, APOBEC2, Apoptosis, Brn-3c, C18orf18, CA19-9, CCDC154, CGI-96, CGI-99_2700060E02Rik, CLEC-18C, Colorectal Adenocarcinoma Marker, Colorectal Carcinoma, CSDA, DDX10, DDX16, DDX19B, DDX27, DDX47, DDX50, DDX59, DinB, DPY19L3, Dynlt1e, G6Pase-α, Gastric Carcinoma Marker, Glutathione reductase, H2-Q2, HHCM, ILT-5, Kaptin, Klkb1, LOC100039899, LOC100040214, LOC100040682, LOC345630, LOC642361, MRT4, MSH2_Msh2, NFYB, NOP9, Olfr860, PABPC1L, R2, Rae-1δ, RBMX2, Reprimo, RPA135, RPAC2, SKIV2L, Slfn11, Sm, SNM1A, SRp75, TDG, TFIIA, TFIIA-γ, TFIIE-α, TFIIIB, TFIIIB90, THUMPD1, THUMPD2, TMEM163, TMEM45A, TRAPPC4, and TSHZ3.Activator of:
1700019N19Rik, ADAR3, ADRM1, Bmf, BRAF35, Chk1, DDI1, DDX18, DDX46, DDX54, Dmc1, DNA pol η, DnaJA2, EndoV, ERCC1, gp210, Haspin, HMG-1, hMLH3, hnRNP A3, hnRNP J, MCM9, MR1, MSH3_Msh3, Msh6, MYBBP1A, Ncapg, NPM2, PABPC2, PABPC6, PKR, POLR2G, PRAMEF15, Raly, RFC5, Ribosomal Protein L26L1, Ribosomal Protein S3, RPL22L1, STK6, TBK1, TLR3, UDG, YB-1, and ZNF234.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Oxaliplatin, 5 mg | sc-202270 | 5 mg | $110.00 | |||
Oxaliplatin, 25 mg | sc-202270A | 25 mg | $386.00 |